Physician profile
Eden M Miller
NPI 1114997988
$1,654,967.68
in general payments reported to CMS, 2019-2025
53 companies · $309K in 2025
The $309K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211K · 2020: $220K · 2021: $186K · 2022: $254K · 2023: $225K · 2024: $249K · 2025: $309K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $519K · Consulting Fee: $99K · Travel and Lodging: $78K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Food and Beverage: $24K · Honoraria: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $518,555.65 |
| Consulting Fee | $98,820.68 |
| Travel and Lodging | $77,811.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $52,882.25 |
| Food and Beverage | $24,009.31 |
| Honoraria | $11,543.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $634,952.26 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $290,899.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $252,741.38 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Afinion 2 |
| Insulet Corporation | $147,500.27 | 2020-2025 | Omnipod, Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72,548.87 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70,544.00 | 2021-2025 | |
| Eli Lilly and Company | $51,748.53 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $40,536.61 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $26,583.48 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $19,431.68 | 2019-2022 | |
| Embecta Corp. | $9,889.59 | 2023-2025 | Bd Nano 2nd Gen Pen Needle |
| Lifescan, INC. | $9,809.00 | 2022-2025 | |
| Novo Nordisk As | $6,218.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $5,259.52 | 2019-2021 | |
| Becton, Dickinson and Company | $4,596.25 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eden Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.